China clinical trial is very behind India's. SFDA is very restrictive on clinical trial for foreign companies, especially first in human. Meanwhile, pharma's still hesitate to put more phase III in China due to the quality of data and GCP compliance.
WUxi pharmatech is going down stream now. They just build a tox facility in suzhou and will be in operation next year.